Bank of New York Mellon Corp reduced its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 1.2% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 18,431,108 shares of the biopharmaceutical company’s stock after selling 223,524 shares during the period. Bank of New York Mellon Corp owned about 1.10% of Bristol-Myers Squibb worth $1,002,282,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in the stock. Guggenheim Capital LLC boosted its position in shares of Bristol-Myers Squibb by 10.0% in the fourth quarter. Guggenheim Capital LLC now owns 941,383 shares of the biopharmaceutical company’s stock valued at $55,014,000 after buying an additional 85,611 shares in the last quarter. Focused Wealth Management Inc boosted its position in shares of Bristol-Myers Squibb by 11.8% in the fourth quarter. Focused Wealth Management Inc now owns 9,747 shares of the biopharmaceutical company’s stock valued at $570,000 after buying an additional 1,028 shares in the last quarter. Ellington Management Group LLC purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at about $1,005,000. Ancora Advisors LLC boosted its position in shares of Bristol-Myers Squibb by 18.6% in the fourth quarter. Ancora Advisors LLC now owns 102,513 shares of the biopharmaceutical company’s stock valued at $5,991,000 after buying an additional 16,063 shares in the last quarter. Finally, Seven Eight Capital LP purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at about $1,575,000. 69.79% of the stock is currently owned by institutional investors.
Bristol-Myers Squibb Company (NYSE:BMY) traded down 1.41% on Thursday, hitting $56.59. 5,134,568 shares of the stock were exchanged. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $61.30. The company’s 50-day moving average is $55.82 and its 200-day moving average is $54.60. The company has a market cap of $92.80 billion, a PE ratio of 20.67 and a beta of 1.17.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same period last year, the company posted $0.69 EPS. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. On average, analysts predict that Bristol-Myers Squibb Company will post $2.97 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th were given a dividend of $0.39 per share. The ex-dividend date was Wednesday, July 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.76%. Bristol-Myers Squibb’s payout ratio is presently 56.73%.
A number of equities analysts have recently weighed in on BMY shares. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday. Vetr cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 price target on the stock. in a research note on Wednesday. BidaskClub raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Monday, June 26th. Finally, BMO Capital Markets cut shares of Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 price target on the stock. in a research note on Wednesday, May 3rd. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $62.69.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II acquired 6,000 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The stock was purchased at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the transaction, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.23% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.
